Journals / Ankara Üniversitesi Tıp Fakültesi Mecmuası / 2017 / Cilt: 70 - Sayı: 1

Diabetic Cardiomyopathy and Prolyl Hydroxylases

Diyabetik Kardiyomiyopati ve Prolil Hidroksilazlar

Pages
29–36
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Increment ofPHD-based research in diabetes may help the production of valuable knowledge about preventiveand therapeutical strategies in diabetes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic cardiomyopaty (DCMP) is described as ventricular dysfunction seen in diabetic patientswhich manifests itself without any coronary artery disease and hypertension.
📊
Key Findings & Data:Generally systolic dysfunction is a latesymptom which is seen in patients who have significant diastolic dysfunction.DCMP has a very complex pathophysiology which can be indexed in many titles.
💡
Conclusion & Impact:Increment ofPHD-based research in diabetes may help the production of valuable knowledge about preventiveand therapeutical strategies in diabetes.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic cardiomyopaty (DCMP) is described as ventricular dysfunction seen in diabetic patientswhich manifests itself without any coronary artery disease and hypertension. One may observe intersititialfibrosis, myocyte hypertrophy and contractile protein glycation in DCMP. Diastolic dysfunctionis the earliest and most of the time only symptom of DCMP. Generally systolic dysfunction is a latesymptom which is seen in patients who have significant diastolic dysfunction.DCMP has a very complex pathophysiology which can be indexed in many titles. We focused on HIFVEGF-Angiogenesisaxis which contains prolyl hydroxilases. In diabetes HIF response to hypoxia isblunted and it is known that this alteration is an important contributor to DCMP prognosis.Prolyl hydroxilases are enzymatic molecules (PHDs) which, uses molecular oxygen as cofactor and ifoxygen is abundant they degrade HIF-α (hypoxia induced factor-α) subunit. They have an importantrole in cellular oxygen homeostasis and HIF response to hypoxia. In hypoxic conditions, PHD becomesinactive that saves HIF-1α from degradation and HIF-1α unites with β subunit to form HIF-1 molecule.This phenomenon is named as “HIF stabilisation”. Stabilised HIF-1 molecule modifies lots of protein’stranscription rate in the cell. Activation of HIF’s downstream targets, lowers the energy and oxygenconsumption and increases the delivery of oxygen to the cell which protects the cell from hypoxicdamage.The genomic profile generated with HIF activation has cardioprotective effect in DCMP. HIF overexpressinggenetic models, hypoxia application, PHD inhibitors and PHD silencing methods is usedto activate HIF system.There are limited number of studies in literature about the effect of diabetes on PHDs. Increment ofPHD-based research in diabetes may help the production of valuable knowledge about preventiveand therapeutical strategies in diabetes.

Özet

Diyabetik kardiyomiyopati (DKMP), diyabet hastalarında koroner arter hastalığı ve hipertansiyondan bağımsız olarak geli?en ventriküler disfonksiyon olarak ifade edilmektedir. Kalp dokusunda görülen, intersitisyal fibrozis, miyosit hipertrofisi ve artmı? kontraktil protein glikozilasyonu DKMP'de görülen kardiyak patolojilere örnek te?kil eder. Sistolik disfonksiyon DKMP'de genellikle geç ve belirgin diyastolik disfonksiyonu olan hastalarda görülen bir bulgudur. DKMP'nin birçok ba?lıktan olu?an oldukça karma?ık bir patofizyolojisi vardır. Bu derlemede prolil hidroksilazların da içerisinde bulunduğu HIF-VEGF-anjiyogenez aksındaki bozulmalar üzerinde yoğunla?ılmı?tır. Diyabette hipoksiye verilen HIF yanıtının bozulduğu ve bu deği?imin DKMP'nin patogenezinde önemli bir yer tuttuğu bilinmektedir. Prolil hidroksilazlar (PHD'ler), moleküler oksijeni kofaktör olarak kullanan, oksijen varlığında HIF-? (hipoksi ile indüklenen faktör-?) altbirimini degrade eden enzim yapılı moleküllerdir. Hücresel oksijen homeostazında ve hipoksiye verilen HIF cevabında önemli bir yere sahiptirler. Hipoksik ko?ullarda PHD enzimi inaktif hale gelir ve degradasyondan kurtulan HIF-1?, ? alt birimi ile birle?erek HIF-1 molekü- lünü olu?turur. Bu olaya "HIF stabilizasyonu" adı verilir. Stabilize olan HIF-1 molekülü hücredeki birçok proteinin transkripsiyonunu modifiye eder. HIF'in alt hedeflerinin aktivasyonu hücrenin enerji ve oksijen tüketimini azaltır ve hücreye oksijen arzını arttırır, böylece hipoksik sürecin en az hasarla atlatılması sağlanır. HIF aktivasyonu sonucu açığa çıkan genomik profilin DKMP'de koruyucu etkileri olduğu bilinmektedir. HIF sistemini aktive etmek için HIF overekspresyonu yapılan genetik modeller, hipoksi uygulaması, PHD inhibitörleri ve PHD geninin susturulması gibi yöntemler kullanılmaktadır. Literatürde diyabetin PHDlere olan etkisi ile ilgili az sayıda çalı?ma bulunmaktadır. Diyabette PHD merkezli ara?tırmaların artması diyabette önleyici ve tedavi edici stratejilerin geli?tirilmesi açısından önemli bilgiler üretilmesine açık bir alandır.

🔖

Cite This Article

FIÇICILAR, H., AKAT, F. (2022). Diabetic Cardiomyopathy and Prolyl Hydroxylases. Ankara Üniversitesi Tıp Fakültesi Mecmuası, Cilt: 70 - Sayı: 1, 29–36. https://ajindex.com/articles/443684

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (18)

  1. Melmed S, Polonsky KS, Larsen PR, et al. William's Textbook of Endocrinology, 13th edition., Phidelphia: Elsevier/Saunders. 2016; 1371–1435
  2. Lambert P, Bingley PJ. What is Type 1 Diabetes? Medicine 2002; 30: 1–5
  3. IDF (International Diabetes Federation). International Diabetes Atlas 2015; ISBN: 978-2-930229-81-2
  4. Murarka S, Mohaved MR. Diabetic Cardiomyopathy. Journal of Cardiac Failure 2010: 16(12): 971-979
  5. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30(6): 595-602
  6. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 2000; 101: 2271-2276
  7. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34
  8. Das AK, Das JP, Chandrasekar S. Specific heart muscle disease in diabetes mellitus functional structural correlation. Int J Cardiol 1987; 17: 299-302
  9. Nunoda S, Genda A, Sugihara N, et al. Quantitative approach to the histopathology of the biopsied right venticlular myocardium in patients with diabetes mellitus. Heart Vessels 1985; 1: 43-47
  10. Syrovy I, Hodny Z. Nonenzymatic glycosylation of myosin: effects of diabetes and ageing. Gen Physiol Biophys 1992; 11: 301-307
  11. Hayat SA, Patel B, Khattar RS, et al. Diabetic cardiomyopathy: mechanisms diagnosis and treatment. Clinical Science 2004; 107: 539-557
  12. Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977; 60: 884-899
  13. Mildenberger RR Bar-Shlomo B, Druck MN, et al. Clinically unrecognized dysfunction in young diabetic patients. J Am Coll Cardiol 1984; 4: 234-238
  14. Yılmaz S, Canpolat U, Aydoğdu S, et al. Diabetic Cardiomyopathy; Summary of 41 Years. Korean Circ J 2015; 45(4):266-272
  15. Trachanas K, Sideris S, Aggeli C, et al. Diabetic Cardiomyopathy: From Pathophysiology to Treatment. Hellenic J Cardiol 2014; 55: 411-421
  16. Huynh K, Bernardo BC, McMullen JR, et al. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacology & Therapeutics 2014; 142: 375–415
  17. Joffe II, Travers KE, Perreault-Micale CL, et al. Abnormal cardiac function in the streptozotocin-induced, non–insulin-dependent diabetic rat. J Am Coll Cardio 1999; 34: 2111-2119
  18. Kanagy NL. Vascular effects of intermittent hypoxia. ILAR J 2009;